iSpecimen Inc. (ISPC)
NASDAQ: ISPC · Real-Time Price · USD
1.230
-0.020 (-1.60%)
Apr 28, 2025, 4:00 PM EDT - Market closed
iSpecimen Revenue
In the year 2024, iSpecimen had annual revenue of $9.29M, down -6.42%. iSpecimen had revenue of $1.48M in the quarter ending December 31, 2024, a decrease of -42.70%.
Revenue (ttm)
$9.29M
Revenue Growth
-6.42%
P/S Ratio
0.09
Revenue / Employee
$387,130
Employees
24
Market Cap
3.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ISPC News
- 3 months ago - iSpecimen Secures Suppliers for COVID-style hMPV Outbreak - Newsfile Corp
- 4 months ago - iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens - Newsfile Corp
- 4 months ago - iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers - Newsfile Corp
- 4 months ago - iSpecimen Appoints Robert Lim as CEO and Director - Newsfile Corp
- 6 months ago - iSpecimen Named Top Competitor in $4.4 Billion USD Market - Newsfile Corp
- 6 months ago - iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually - GlobeNewsWire
- 6 months ago - iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 months ago - iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire